Y-Intercept (HK)’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.88M | Buy |
51,738
+27,138
| +110% | +$987K | 0.05% | 636 |
|
|
2025
Q1 | $891K | Sell |
24,600
-2,095
| -8% | -$75.9K | 0.06% | 447 |
|
|
2024
Q4 | $1.12M | Buy |
26,695
+7,544
| +39% | +$317K | 0.07% | 383 |
|
|
2024
Q3 | $1.06M | Buy |
19,151
+12,617
| +193% | +$701K | 0.07% | 426 |
|
|
2024
Q2 | $269K | Sell |
6,534
-4,590
| -41% | -$189K | 0.01% | 1066 |
|
|
2024
Q1 | $519K | Buy |
+11,124
| New | +$519K | 0.04% | 694 |
|
|
2023
Q4 | – | Sell |
-15,442
| Closed | -$551K | – | 1581 |
|
|
2023
Q3 | $551K | Buy |
+15,442
| New | +$551K | 0.05% | 531 |
|
|
2022
Q1 | – | Sell |
-2,998
| Closed | -$252K | – | 908 |
|
|
2021
Q4 | $252K | Buy |
+2,998
| New | +$252K | 0.06% | 448 |
|
|
2021
Q3 | – | Sell |
-5,294
| Closed | -$505K | – | 861 |
|
|
2021
Q2 | $505K | Buy |
5,294
+943
| +22% | +$90K | 0.13% | 268 |
|
|
2021
Q1 | $488K | Buy |
4,351
+1,182
| +37% | +$133K | 0.13% | 263 |
|
|
2020
Q4 | $458K | Buy |
+3,169
| New | +$458K | 0.19% | 181 |
|